JA Ledermann
University College London
H-index: 90
Europe-United Kingdom
Top articles of JA Ledermann
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
154 A randomized phase III trial of induction chemotherapy followed by chemoradiation compared with chemoradiation alone in locally advanced cervical cancer. The GCIG INTERLACE … | Mary Mc Cormack Dolores Gallardo Rincon Gemma Eminowicz Patricia Diez Laura Farrelly | 2024/3/1 | |
MEK 1 inhibition and bleeding in hereditary haemorrhagic telangiectasia | British Journal of Haematology | Claire L Shovlin Dilip Patel Adrianna Bielowka Jonathan A Ledermann Atieh Modarresi | 2024/1 |
270 Survival outcomes following cytoreductive surgery in advanced ovarian cancer patients: prognosis is better predicted by completeness of resection than by disease stage | Osnat Elyashiv Radha Graham Nicholas Counsell Nick Jayanth Lauren Berg | 2024/3/1 | |
Monitoring clone dynamics and reversibility in clonal haematopoiesis and myelodysplastic neoplasm associated with PARP inhibitor therapy—a role for early monitoring and … | Leukemia | Ellen Nuttall Musson Rowan E Miller Marc R Mansour Michelle Lockley Jonathan A Ledermann | 2024/1 |
Perspectives of Healthcare Professionals on the Management and Treatment of Advanced Ovarian Cancer in the UK: Results From the KNOW-OC Survey | Clinical Oncology | Christina Fotopoulou M Hall R Lord R Miller S Sundar | 2024/1/1 |
ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease | Annals of Oncology | JA Ledermann X Matias-Guiu F Amant N Concin B Davidson | 2024/3/1 |
Hidden in plain sight–Survival consequences of baseline symptom burden in women with recurrent ovarian cancer | Gynecologic Oncology | Felicia Roncolato Madeleine T King Rachel L O'Connell Yeh Chen Lee Florence Joly | 2024/6/1 |
Ofranergene obadenovec (Ofra-Vec, VB-111) with weekly paclitaxel for platinum-resistant ovarian cancer: Randomized controlled phase III trial (OVAL Study/GOG 3018) | Journal of clinical oncology | Rebecca C Arend Bradley J Monk Ronnie Shapira-Frommer Ashley F Haggerty Edwin A Alvarez | 2024/1/10 |
Best original research presented at the 24th European Congress on Gynaecological Oncology—Best of ESGO 2023 | Joanna Kacperczyk-Bartnik Nicolò Bizzarri Tibor Andrea Zwimpfer Houssein El Hajj Martina Aida Angeles | 2024/4/1 | |
Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly … | Journal of Clinical Oncology | Angelina Tjokrowidjaja ML Friedlander Jonathan A Ledermann Robert L Coleman Mansoor R Mirza | 2024/1 |
110 PROMPT: phase II trial of maintenance pembrolizumab following weekly paclitaxel for recurrent ovarian, fallopian tube or peritoneal cancer | Tami Grunewald Rowan Miller Laura Tookman Iain Mcneish Rene Roux | 2024/3/1 | |
Self-supervised deep learning for highly efficient spatial immunophenotyping | EBioMedicine | Hanyun Zhang Khalid AbdulJabbar Tami Grunewald Ayse U Akarca Yeman Hagos | 2023/9/1 |
Left Ventricular Ejection Fraction in Patients With Ovarian Cancer Treated With Avelumab, Pegylated Liposomal Doxorubicin, or Both | The Oncologist | Marc P Bonaca Javid J Moslehi Jonathan A Ledermann Elisabete Michelon Caimiao Wei | 2023/10/1 |
Randomized controlled phase III trial of weekly paclitaxel±ofranergene obadenovec (VB-111) for platinum-resistant ovarian cancer (OVAL Study/GOG 3018). | Rebecca Christian Arend Bradley J Monk Ronnie Shapira-Frommer Angeles Alvarez Secord Thomas J Herzog | 2023/6/1 | |
Interviews conducted at the European Society of Gynaecological Oncology 2022 Congress: a ENYGO-IJGC Fellows initiative | International Journal of Gynecological Cancer | Martina Aida Angeles Felix Boria Alexander B Shushkevich Nicolò Bizzarri Charalampos Theofanakis | 2023 |
An easy, fast, and accurate way for implementing the standards of care for the management of patients with endometrial carcinoma into daily clinical practice: the ESGO mobile app | International Journal of Gynecologic Cancer | Thomas Gaillard Richard Schwameis Enora Laas-Faron Tali Eisenberg-Nissim Xavier Matias-Guiu | 2023/8/1 |
# 159 ICON8B: GCIG phase III randomised trial comparing weekly dose-dense chemotherapy+ bevacizumab to three-weekly chemotherapy+ bevacizumab in first-line high-risk stage III … | Andrew Clamp Iain Mcneish Rosemary Lord Marcia Hall Sharadah Essapen | 2023/9/1 | |
Response to letter to the editor “AML and MDS associated with PARP inhibitor treatment of ovarian cancer” | Gynecologic Oncology | David M O'Malley Jonathan A Ledermann Robert L Coleman | 2023/4/1 |
Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline☆ | Annals of Oncology | C Sessa J Balmaña SL Bober Maria-Joao Cardoso N Colombo | 2023/1/1 |
# 66 Survival of PARP inhibitor (PARPi) naïve ovarian cancer patients with a BRCA-mutation receiving maintenance olaparib after chemotherapy for first recurrence. An … | Jonathan A Ledermann Isabelle Ray-Coquard Richard Penson Chee Lee Amit Oza | 2023/9/1 |
